JBIO
Jade BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
JBIO vs peer average
40/100
JBIO vs. peer average (D vs. C)
Grade spread
A 1 · B 1 · C 2 · D 5 · F 1
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
VERA is the first available peer comparator.
Direct IgA-nephropathy competitor through atacicept, a BAFF/APRIL inhibitor, but substantially further along clinically and commercially; its results are a competitive benchmark, not a like-for-like valuation multiple. [Vera investor relations](https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-receives-fda-accelerated-approval-trutaknatm)
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
JBIO
Jade Biosciences
VERA
Vera Therapeutics
Grade
D
C
Momentum
14
21
Value
41
41
Sentiment
53
74
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Mixed
Grade position vs VERA
JBIO / VERA
Grade Position
Below peers
JBIO vs. peer average (D vs. C)
40/100
Momentum
14
VERAValue
41
JBIOSentiment
53
VERARotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs JBIO
VERA is the first peer returned for this comparison set.